Accuray Future Growth

Future criteria checks 3/6

Accuray wird ein jährliches Wachstum der Gewinne und Einnahmen um 96.2% bzw. 3.9% prognostiziert, während der Gewinn pro Aktie um 96.7% auf grow steigen dürfte.

Key information

108.5%

Earnings growth rate

108.6%

EPS growth rate

Medical Equipment earnings growth	16.1%
Revenue growth rate	5.7%
Future return on equity	n/a
Analyst coverage	Low
Last updated	13 Feb 2024

Recent future growth updates

Recent updates

Is Accuray (NASDAQ:ARAY) A Risky Investment?

Feb 03

Why Investors Shouldn't Be Surprised By Accuray Incorporated's (NASDAQ:ARAY) 26% Share Price Plunge

Aug 17

More Progress Evident At Accuray, But Sustainability And Follow-Through Remain Key

Nov 30

Accuray (NASDAQ:ARAY) Is Looking To Continue Growing Its Returns On Capital

Sep 28

Accuray: As Usual, Two Steps Forward, One-And-Three-Quarters Steps Back

Aug 20

Should You Be Adding Accuray (NASDAQ:ARAY) To Your Watchlist Today?

Jun 16

More 'Hurry Up And Wait' For Accuray, But The China Opportunity Is Coming Through

Jun 08

We Like These Underlying Return On Capital Trends At Accuray (NASDAQ:ARAY)

May 31

Accuray inks new $120M five-year revolving credit facility

May 07

Should You Think About Buying Accuray Incorporated (NASDAQ:ARAY) Now?

Apr 28

Accuray names Jean-Philippe Pignol chief medical & technology officer

Apr 26

Earnings and Revenue Growth Forecasts

NasdaqGS:ARAY - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2026	515	19	N/A	N/A	2
6/30/2025	489	13	N/A	N/A	3
6/30/2024	462	-8	N/A	N/A	4
12/31/2023	447	-15	8	20	N/A
9/30/2023	455	-7	-6	7	N/A
6/30/2023	448	-9	3	16	N/A
3/31/2023	439	-10	-4	2	N/A
12/31/2022	417	-12	-50	-44	N/A
9/30/2022	419	-10	2	6	N/A
6/30/2022	430	-5	-7	-2	N/A
3/31/2022	431	-13	4	8	N/A
12/31/2021	437	-12	43	46	N/A
9/30/2021	418	-8	30	33	N/A
6/30/2021	396	-6	36	39	N/A
3/31/2021	380	5	49	51	N/A
12/31/2020	377	8	21	23	N/A
9/30/2020	379	14	17	20	N/A
6/30/2020	383	4	-5	-1	N/A
3/31/2020	405	3	-15	-11	N/A
12/31/2019	409	-1	-11	-6	N/A
9/30/2019	413	-17	-40	-36	N/A
6/30/2019	419	-16	-34	-30	N/A
3/31/2019	415	-16	-16	-11	N/A
12/31/2018	412	-24	-6	0	N/A
9/30/2018	410	-24	6	14	N/A
6/30/2018	405	-24	12	18	N/A
3/31/2018	403	-28	7	14	N/A
12/31/2017	401	-24	-7	-3	N/A
9/30/2017	388	-29	N/A	-7	N/A
6/30/2017	383	-30	N/A	0	N/A
3/31/2017	366	-32	N/A	-4	N/A
12/31/2016	374	-26	N/A	0	N/A
9/30/2016	396	-22	N/A	12	N/A
6/30/2016	399	-26	N/A	31	N/A
3/31/2016	406	-24	N/A	7	N/A
12/31/2015	398	-28	N/A	17	N/A
9/30/2015	387	-32	N/A	10	N/A
6/30/2015	380	-40	N/A	-14	N/A
3/31/2015	380	-44	N/A	-13	N/A
12/31/2014	380	-46	N/A	0	N/A
9/30/2014	375	-42	N/A	-3	N/A
6/30/2014	369	-35	N/A	0	N/A
3/31/2014	352	-44	N/A	-3	N/A
12/31/2013	326	-71	N/A	-37	N/A
9/30/2013	310	-91	N/A	-64	N/A
6/30/2013	316	-97	N/A	-66	N/A

Analyst Future Growth Forecasts

Einkommen vs. Sparrate: ARAY wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.2%).

Ertrag vs. Markt: ARAY wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: ARAY wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: ARAYDie Einnahmen des Unternehmens (3.9% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.1% pro Jahr).

Hohe Wachstumseinnahmen: ARAYDie Einnahmen des Unternehmens (3.9% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Earnings per Share Growth Forecasts

Future Return on Equity

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ARAY in 3 Jahren voraussichtlich hoch sein wird

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Accuray Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Accuray Incorporated Reaffirms Revenue Guidance for the Third Quarter and Full Fiscal Year 2024

Forecast breakeven date pushed back to 2025

Accuray Incorporated Provides Revenue Guidance for Fiscal Year 2024

Accuray Incorporated Reiterates Earnings Guidance for the Year 2023

Accuray Incorporated Re-Affirms Guidance for Year 2023

Recent updates

Accuray Incorporated Announces New Data from Two Clinical Studies Indicate High-Risk and Recurrent Prostate Cancers Can Be Effectively Treated in 5 Days Using the Accuray CyberKnife System

New minor risk - Shareholder dilution

Is Accuray (NASDAQ:ARAY) A Risky Investment?

Second quarter 2024 earnings: EPS misses analyst expectations

Accuray Incorporated Reaffirms Revenue Guidance for the Third Quarter and Full Fiscal Year 2024

Accuray Incorporated to Report Q2, 2024 Results on Jan 31, 2024

President recently sold US$162k worth of stock

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

President recently sold US$99k worth of stock

Accuray Incorporated to Report Q1, 2024 Results on Nov 07, 2023

Accuray Announces Approval of the Tomo C Radiation Treatment Delivery System by China's National Medical Products Administration

Accuray Incorporated, Annual General Meeting, Nov 09, 2023

Why Investors Shouldn't Be Surprised By Accuray Incorporated's (NASDAQ:ARAY) 26% Share Price Plunge

Full year 2023 earnings: EPS misses analyst expectations

Forecast breakeven date pushed back to 2025

Accuray Incorporated Provides Revenue Guidance for Fiscal Year 2024

Accuray Incorporated to Report Q4, 2023 Results on Aug 09, 2023

President recently sold US$65k worth of stock

Insider recently sold US$93k worth of stock

Accuray Incorporated Announces New Data Presented at the European Society for Radiotherapy and Oncology

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

These 4 Measures Indicate That Accuray (NASDAQ:ARAY) Is Using Debt Extensively

The Return Trends At Accuray (NASDAQ:ARAY) Look Promising

Accuray Incorporated Announces Data from Randomized, Multicenter Trial PACE-A

High number of new directors

Accuray Incorporated Reiterates Earnings Guidance for the Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Accuray Incorporated Announces the Appointment of Robert C. Kill to its Board of Directors

Accuray Incorporated to Report Q2, 2023 Results on Feb 01, 2023

Accuray Incorporated Announces First Patient Treatments in New Zealand with the CyberKnife(R) System

Accuray Incorporated Announces Intent to Resign from Position as Chief Accounting Officer and Principal Accounting Officer, Effective January 3, 2023

Accuray (NASDAQ:ARAY) Takes On Some Risk With Its Use Of Debt

First quarter 2023 earnings: EPS and revenues miss analyst expectations

President recently sold US$76k worth of stock

Accuray Incorporated Re-Affirms Guidance for Year 2023

Accuray Announces Tomo C Registration Submission to China's National Medical Products Administration

High number of new directors

Accuray (NASDAQ:ARAY) Is Doing The Right Things To Multiply Its Share Price

Japanese Ministry of Health, Labor and Welfare Approves Reimbursement for the Cyberknife(R) System for the Treatment of Trigeminal Neuralgia

Accuray Incorporated to Report Q1, 2023 Results on Nov 02, 2022

Accuray Incorporated Announces Data Published in The Lancet Oncology Indicate Men With Prostate Cancer Treated With the Accuray CyberKnife® Platform Experienced a Lower Incidence of Bladder Side Effects Than Those Treated With Conventional Linear Accelerators

Accuray Incorporated, Annual General Meeting, Nov 10, 2022

Accuray launches CyberKnife platform in Africa for cancer patients

Richard R. Pettingill Not to Stand for Re-Election as Class I Director of Accuray Incorporated

Accuray Incorporated Appoints Seth Blacksburg as Chief Medical Officer

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Accuray Incorporated Provides Revenue Guidance for Year 2023

Accuray GAAP EPS of -$0.04 beats by $0.03, revenue of $110.02M beats by $4.7M

Accuray Incorporated to Report Q4, 2022 Results on Aug 10, 2022

Accuray CyberKnife® System Real World Data and Clinical Studies Show Benefits in Treatment of Neurological Indications

Here's Why Accuray (NASDAQ:ARAY) Has A Meaningful Debt Burden

Accuray Incorporated(NasdaqGS:ARAY) dropped from Russell 3000E Index

Accuray Incorporated Appoints Franco N. Palomba as Chief Accounting Officer & Controller

Accuray (NASDAQ:ARAY) Might Have The Makings Of A Multi-Bagger

High number of new directors

Accuray: Nothing Special

Accuray Appoints Sandeep Chalke as SVP, Chief Commercial Officer

Accuray Incorporated Announces That Clinical Studies Continue to Validate the Versatility of the Company's Cyberknife® and Tomotherapy® Platforms

High number of new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations

Accuray Incorporated Re-Affirms Earnings Guidance for the Fiscal Year 2022

Price target increased to US$8.30

Accuray Incorporated to Report Q3, 2022 Results on Apr 27, 2022

National Institute for Health and Care Excellence Endorses Radiosurgery Treatments for Trigeminal Neuralgia, Supporting Accuray Incorporated's CyberKnife System Indications for Use

Accuray Incorporated Announces Data from Phase III, Randomized Controlled Trial, TomoBreast

Accuray Once Again Hits The Reset Button On Its Progress

A Look At The Fair Value Of Accuray Incorporated (NASDAQ:ARAY)

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Accuray Incorporated Provides Earnings Guidance for the Fiscal Year Ending June 30, 2022

Returns Are Gaining Momentum At Accuray (NASDAQ:ARAY)